Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
Gyre Pharmaceuticals Receives IND Approval from China's NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Gyre Therapeutics: Under The Radar Biotech Has A Shot At MASH Approval, In Time
Gyre Therapeutics Reports Full Year 2023 Financial Results
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum